GRELA, Wiktor, NIEWIADOMSKA, Jagoda, FURTAK, Daria, TULEJ, Dawid, GŁOGOWSKA, Paulina, DZIEDZIC, Alicja, GNIAŹ, Natalia, MARCINIUK, Dominika, MARKO, Natalia and GÓRSKA, Aleksandra. Exploring the Gut Microbiome's Influence on Colorectal Cancer Development: A Review of Current Knowledge and Future Directions. Journal of Education, Health and Sport. 2024;70:55587. eISSN 2391-8306.
https://dx.doi.org/10.12775/JEHS.2024.70.55587
https://apcz.umk.pl/JEHS/article/view/55587

The journal has had 40 points in Minister of Science and Higher Education of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of 05.01.2024 No. 32318. Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical culture sciences (Field of medical and health sciences); Health Sciences (Field of medical and health sciences).
Punkty Ministerialne 40 punktów. Załącznik do komunikatu Ministra Nauki i Szkolnictwa Wyższego z dnia 05.01.2024 Lp. 32318. Posiada Unikatowy Identyfikator Czasopisma: 201159. Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu).© The Authors 2024;
This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland

The authors declare that there is no conflict of interests regarding the publication of this paper.
Received:21.10.2024. Revised: 24.10.2024. Accepted: 28.10.2024. Published: 29.10.2024.

Exploring the Gut Microbiome's Influence on Colorectal Cancer Development and Management: A Review of Current Knowledge and Future Directions

Wiktor Grela [WG]
grelawiktor@gmail.com
ORDCID 0009-0000-5801-5756
Medical University of Lublin, Poland
al. Racławickie 1, 20-059 Lublin, Poland

Jagoda Niewiadomska [JN]
malwatexass@wp.pl
ORCID 0009-0003-2219-984X
Medical University of Lublin, Poland
al. Racławickie 1, 20-059 Lublin, Poland

Daria Furtak [DF]
dariafurtak@gmail.com
ORCID 0000-0003-0768-9800
Medical University of Lublin, Poland
al. Racławickie 1, 20-059 Lublin, Poland

Dawid Tulej [DT]
dawid.tulej2000@gmail.com
ORCID 0000-0002-5711-3423
Medical University of Lublin, Poland
al. Racławickie 1, 20-059 Lublin, Poland

Paulina Głogowska [PG]
glogowska.paulina1@gmail.com
ORCID 0009-0002-3003-4466
Medical University of Lublin, Poland
al. Racławickie 1, 20-059 Lublin, Poland

Alicja Dziedzic [AD]
alicja.dziedzic1109@gmail.com
ORCID 0009-0001-0460-4106
Medical University of Lublin, Poland
al. Racławickie 1, 20-059 Lublin, Poland 0001-046

Natalia Gniaź [NG]
natalia.gniaz55@gmail.com
ORCID 0009-0008-3329-9770
Medical University of Lublin, Poland
al. Racławickie 1, 20-059 Lublin, Poland

Dominika Marciniuk [DM]
marciniukd@gmail.com
ORCID 0009-0000-0710-8485
Medical University of Lublin, Poland
al. Racławickie 1, 20-059 Lublin, Poland

Natalia Marko [NM]
markonatalia26@gmail.com
ORCID 0009-0004-7815-4592
Medical University of Lublin, Poland
al. Racławickie 1, 20-059 Lublin, Poland

Aleksandra Górska [AG]
ola.gorska6@gmail.com
ORCID 0009-0004-0141-2821
Medical University of Lublin, Poland
al. Racławickie 1, 20-059 Lublin, Poland

Abstract

Introduction

Colorectal cancer (CRC) is a significant global health concern, ranking as the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths worldwide, with over 1.9 million new cases and nearly 935,000 deaths annually. The rise in CRC incidence is attributed to various lifestyle changes, including dietary shifts, sedentary behavior, and increased obesity rates. These factors underscore the urgent need for new preventive strategies targeting the underlying mechanisms of CRC development.

Purpose

This review evaluates the intricate relationship between the gut microbiome and CRC, aiming to enhance our understanding of how microbial diversity and composition contribute to CRC pathogenesis.

State of Knowledge

Studies reveal a correlation between the onset and progression of CRC and changes in microbial diversity and specific taxa. In CRC patients, the presence of Fusobacterium nucleatum is linked to inflammation and poor prognosis, while Bacteroides fragilis is associated with promoting colitis and carcinogenesis. The Human Microbiome Project's findings reveal that unique microbial communities can impact inflammation and tumor growth. Meta-analyses underline

the crucial role of microbial diversity, influenced by diet and health status, in cancer prevention and progression, particularly in CRC.

Conclusions

Understanding the interactions between the microbiome, diet, and host health is crucial for developing targeted treatment strategies and precision diagnostics for CRC. Insights from microbiome research could significantly improve patient outcomes in CRC management. Further high-quality studies are essential to fully elucidate the therapeutic potential of the microbiome in CRC treatment.

Keywords

gut microbiota; colorectal cancer; microbial diversity; inflammatory responses; precision medicine

---

Introduction and Purpose

Globally, there are approximately 1.9 million new cases and 935,000 deaths annually from colorectal cancer, making it the third most common diagnosed cancer and the second leading cause of cancer deaths. In developed countries, it causes considerable morbidity and mortality. The gut microbiota, as a complex and diverse community of microorganisms in the gastrointestinal tract, plays a pivotal role in the development and progression of CRC, influenced by genetic, environmental, and lifestyle factors [1,2].

Historical Context

Over the last century, the study of the gut microbiome and its impact on health and disease has undergone substantial advancements. In the early 20th century, researchers like Elie Metchnikoff first proposed the idea of intestinal flora and its benefits for human health. Metchnikoff proposed that consuming fermented foods would foster beneficial gut bacteria growth, thereby improving overall health and potentially extending lifespan. This early research paved the way for investigations into the gut microbiota's involvement in CRC and other diseases [3].

As microbiome research progressed, technological advancements played a crucial role in revolutionizing the field. The advent of molecular techniques, particularly metagenomics and 16S rRNA sequencing, transformed our understanding of the microbial communities inhabiting

the human gut. These technologies enabled researchers to identify and characterize previously uncultivable microbial species, providing insights into the complex interplay between the gut microbiota and human health. For example, the Human Microbiome Project, launched in 2007, aimed to map the microbial communities across different human body sites, including the gastrointestinal tract [4]. This initiative highlighted the remarkable diversity of gut microbes and their potential influence on health outcomes, including CRC [5].

Technological innovations fueled the microbiome research advancements. 16S rRNA sequencing and metagenomics have revolutionized the study of gut microbial communities. With these technologies, researchers were able to identify and characterize hitherto uncultivable microbial species, shedding light on the intricate relationship between the gut microbiota and human health. Launched in 2007, the Human Microbiome Project's goal was mapping microbial communities in various human body sites, including the gastrointestinal tract. This initiative showcased the varying gut microbes and their significant effects on health results, including CRC.

Historical advancements in gut health research and technology development have influenced our understanding of CRC. By the mid-20th century, the perspective on CRC was predominantly shaped by genetic and environmental factors, paying scant attention to the impact of the microbiome. The microbiome's critical role in CRC development was increasingly recognized as studies linked specific microbial taxa to inflammatory processes and tumorigenesis. In the early 2000s, the identification of Fusobacterium nucleatum's link to CRC led to a significant turning point, accelerating research into the role of microbial imbalance in cancer development.

CRC is increasingly being recognized as a complex disease influenced by microbial interactions, a perspective that is gaining traction in oncology as a result of ongoing microbiome research. The historical context of microbiome research is continually being reassessed, recognizing the influence of early theorists and the significance of technological advancements in shaping our present knowledge about the gut's role in CRC.

Global Perspectives

CRC incidence rates differ notably among regions due to variations in lifestyle choices, dietary patterns, and socioeconomic conditions. Countries with high meat intake and low fiber consumption are associated with higher colorectal cancer rates, while areas following plant-

based diets, such as parts of Asia, demonstrate lower incidence rates [6]. The increasing disparities in CRC rates highlight the urgent necessity for targeted public health interventions. Supporting healthier diets and microbiome awareness could counteract these tendencies, especially for high-risk groups.

This review examines the relationship between the gut microbiome and CRC, highlighting how microbial diversity alterations and specific bacterial taxa contribute to colorectal tumor initiation and progression. Through comprehending these functions, we strive to offer insights into creating accurate diagnostics and personalized treatment plans for CRC, thus enhancing patient outcomes.

Materials and Methods

This review was based on a thorough exploration of literature from PubMed, Google Scholar, ResearchGate, scientific books, and peer-reviewed articles. This literature search employed keywords including "gut microbiota and colorectal cancer," "microbial diversity in CRC," "gut microbiome's role in tumor development," and "inflammatory responses in colorectal cancer." Research published within the last decade was prioritized to incorporate the most recent findings.

Discussion

The role of the gut microbiome in colorectal cancer (CRC) is becoming clearer as research reveals the significance of microbial diversity and specific taxa in CRC development. The onset and progression of CRC is significantly associated with alterations in gut microbiota composition, which is characterized by decreased diversity and the proliferation of pathogenic taxa [7,8].

Fusobacterium nucleatum: Modulation of Immune Responses and Tumor Progression

F. nucleatum promotes tumor growth by regulating immune responses. Research indicates that F. nucleatum can upregulate matrix metalloproteinase 7 (MMP7) through the MAPK/JNK-AP1 signaling pathway, enhancing the metastatic potential of CRC cells [9]. MMP7 facilitates invasion and promotes metastasis. The bacterium, F. nucleatum, plays a crucial role in both the primary tumor site and the metastatic spread, as well as downregulating the activity of immune cells (TILs and NK cells) to hinder anti-tumor responses. Unchecked CRC cell proliferation results from the immune suppression. F. nucleatum enhances tumor colonization by promoting epithelial cell adhesion.

Bacteroides fragilis: Inflammation and Carcinogenesis

Bacteroides fragilis's enterotoxigenic strain (ETBF) is responsible for colorectal carcinogenesis by inducing chronic inflammation via production of B. fragilis toxin (BFT) and subsequent NF-κB and STAT3 activation, resulting in excessive IL-17, IL-23, and IL-10 overexpression. This cytokine cascade, by inducing DNA damage in epithelial cells via the production of reactive oxygen species (ROS), fosters a pro-tumorigenic environment and initiates cancer. B. fragilis's disruption of gut barrier integrity worsens inflammation by letting harmful bacterial substances penetrate further into the mucosa, fueling a continuous cycle of inflammation and DNA damage [10].

Additional Microbial Species

Enterococcus faecalis produces genotoxic cytolysin causing DNA damage, promoting inflammatory responses that can lead to tumor development; Peptostreptococcus plays a role in CRC through immune response modulation and metabolite production affecting epithelial cells; certain Escherichia coli strains induce inflammation, toxin production, and epithelial cell dysregulation [11].

Discussion of Specific Bacterial Taxa Linked to Inflammatory Responses and Tumor Development

The gut microbiome's composition plays a pivotal role in the genesis of colorectal cancer (CRC). Studies show that decreases in Faecalibacterium prausnitzii and increases in Akkermansia muciniphila are indicative of CRC. Both Fusobacterium nucleatum and Bacteroides fragilis, known bacterial taxa, have been shown to promote CRC through inflammation and DNA damage [12].

Fusobacterium nucleatum promotes tumor growth through modulation of the immune response and creation of a pro-inflammatory microenvironment. Like Bacteroides fragilis, particularly its enterotoxigenic strain (ETBF), inflammatory pathways are triggered to promote epithelial cell proliferation and survival, aiding cancer development. The complex linkages between particular bacterial species and the host's cellular pathways in CRC require thorough comprehension [13].

Understanding the gut microbiome's intricate role in CRC development is essential for creating

effective prevention and treatment methods. The following part explores these in-depth mechanical understandings.

Detailed Mechanistic Insights on Microbial Influence

The intricate link between the gut microbiome and colorectal cancer (CRC) development is facilitated through multiple molecular pathways. Examining these pathways can reveal crucial information on the role particular microbial species play in tumor development and disease advancement.

Molecular Mechanisms

Wnt/β-catenin Pathway

The Wnt/β-catenin signaling pathway plays a crucial role in cellular processes including proliferation, differentiation, and apoptosis. CRC is characterized by dysregulation of this pathway. Fusobacterium nucleatum interacts with the tumor microenvironment, upregulating the Wnt/β-catenin pathway, leading to increased cell proliferation and tumor growth. The bacterium triggers oncogenic activity by binding to host cells via surface adhesins [14,15].

MAPK Signaling Pathway

The mitogen-activated protein kinase (MAPK) signaling pathway plays a crucial role in CRC development. The enterotoxigenic strain (ETBF) of Bacteroides fragilis triggers the MAPK pathway by secreting pro-inflammatory cytokines. These cytokines trigger signaling events that boost epithelial cell growth and longevity. Sustained inflammation resulting from microbial products' chronic activation of the MAPK pathway is a known risk factor for cancer progression [16,17].

NF-κB Pathway

The nuclear factor-kappa B (NF-κB) pathway serves as a central mediator of inflammatory responses. Dysbiosis—characterized by an imbalance of beneficial and pathogenic bacteria—can lead to the overactivation of NF-κB. For example, the *B. fragilis* toxin (BFT) induces the expression of NF-κB by activating various upstream signaling pathways, which in turn results in the production of pro-inflammatory cytokines. This inflammatory milieu fosters a microenvironment conducive to tumor development, facilitating the transition from inflammation to cancer through mechanisms such as DNA damage and genetic mutations [18,19].

Microbiota-Host Interactions

Immune-Modulating Effects of the Microbiome

The gut microbiome substantially impacts the immune response of the host by modulating pro-inflammatory and anti-inflammatory signals. Fusobacterium nucleatum specifically inhibits the functions of tumor-infiltrating lymphocytes (TILs) and natural killer (NK) cells. The impediment of the host's immune response against CRC cells leads to their uncontrolled multiplication [20].

The microbiome can impact systemic inflammation. Dysbiosis causing excessive circulation of gram-negative bacteria's lipopolysaccharides may generate inflammatory responses linked to increased CRC risk. IL-6 and TNF-α, two inflammatory cytokines, can damage the epithelial barrier, increasing permeability and allowing microbial products access to the gut lining. A disruption of the epithelial barrier can allow bacteria and their toxins to enter the systemic circulation, leading to chronic inflammation and heightened cancer risk [21].

Influence on T-Cell Responses

The gut microbiome significantly influences T-cell responses, specifically those of Tregs and effector T cells. Lactobacillus bacteria promote the growth of anti-inflammatory cytokines, leading to the development of immune-tolerant Tregs. Pathogenic bacteria, including Fusobacterium nucleatum, can shift T-cell responses to a pro-inflammatory state, contributing to tumor growth [22].

A modulated T-cell response by the microbiome influences CRC development. Excess effector T-cell responses over regulatory ones can promote inflammation, tissue damage, and create conditions suitable for cancer growth.

Epithelial Barrier Integrity

Preserving the epithelial barrier's integrity is vital for CRC prevention. The gut microbiome enhances tight junction integrity through the generation of SCFAs and other favorable metabolites. Faecalibacterium prausnitzii, a beneficial bacterium, fortifies tight junctions and decreases intestinal permeability by amplifying Short-Chain Fatty Acids (SCFAs) production [23].

Dysbiosis, marked by an excess of harmful bacterial strains, can impair the gut barrier function, causing increased intestinal permeability or "leaky gut." This condition allows harmful substances to enter the bloodstream, triggering systemic inflammation and contributing to CRC risk.

Host-Microbe Interactions

The gut microbiome influences the host immune system beyond TILs and NK cells. Microbial communities regulate specific cytokine profiles, featuring pro-inflammatory cytokines such as IL-6 and TNF-α. Fusobacterium nucleatum triggers the NF-κB signaling pathway, fostering a tumorigenic milieu. Beneficial microbes can boost gut health by increasing the production of anti-inflammatory cytokines and short-chain fatty acids (SCFAs) [24].

Microbiome-Driven Inflammation

Chronic inflammation caused by dysbiosis leads to systemic effects that increase the risk of CRC. The enterotoxigenic strain of Bacteroides fragilis, specifically B. fragilis toxin (BFT), stimulates inflammatory responses by triggering the NF-κB and STAT3 signaling pathways, resulting in excessive cytokine production and epithelial cell growth [25,26]. Inflammatory cascades create an environment that encourages carcinogenesis by instigating genetic mutations due to heightened oxidative stress and DNA damage .

Implications for CRC Development

Dysbiosis, by altering microbial composition and modifying the immune response, hampers the body's ability to regulate tumor growth. In CRC patients, the presence of certain taxa like Fusobacterium nucleatum, linked to dysbiosis, is indicative of a poor prognosis. Analyzing these interactions reveals prospects for therapeutic approaches, including dietary modifications and probiotic administration [27].

Focus on CRC Prevention and Microbiome Modulation

Prebiotics, probiotics, and synbiotics significantly impact the gut microbiome, presenting effective approaches for CRC prevention. Prebiotics stimulate the growth of beneficial gut bacteria by not being digestible. Dietary fibers including inulin, fructooligosaccharides, and resistant starch are common sources. butyrate-producing compounds promote anti-inflammatory effects and gut barrier maintenance through enhanced SCFAs production.

According to Slavin's research [28], a higher fiber intake is linked to increased SCFA levels, lowering colorectal cancer risk.

Probiotics, when administered in proper quantities, provide health benefits to the host as live microorganisms. Studies have shown that strains like Lactobacillus and Bifidobacterium can restore gut microbiota balance, boost immune responses, and impede the growth of CRC-linked pathogens. According to Veettil's (2017) systematic review [29], probiotics effectively decrease adenomatous polyps recurrence, implying their potential value in CRC prevention.

Synbiotics, a mix of prebiotics and probiotics, offer enhanced benefits. The probiotics' survival and activity in the gut are boosted, while the gut environment is optimized. Jadhav et al. (2023) [30] discovered that synbiotic supplementation resulted in a more favorable gut microbiota composition, with an increase in beneficial bacteria and a decrease in detrimental species. Prebiotics, probiotics, and synbiotics could have significant roles in preventing CRC with personalized approaches based on individual microbiome profiles.

Dietary Interventions

Dietary adjustments are essential for optimizing gut health and decreasing colorectal cancer risk. Dietary components can significantly impact gut microbiota, leading to altered CRC outcomes. Consuming fiber is crucial for maintaining a healthy gut microbiome. Consuming high-fiber diets boosts microbial diversity and SCFAs' generation, which in turn reduces inflammation and impedes tumor growth. According to a meta-analysis by Aune et al. [31], a 10% reduction in CRC risk is linked to every 10 g/day rise in dietary fiber intake. The specific types of fiber consumed influence the microbial makeup of the gut.

Polyphenols in fruits, vegetables, and whole grains contribute significantly to gut health. These compounds promote the growth of advantageous intestinal bacteria with prebiotic-like properties. According to a 2008 study by Gómez-Pinilla [32], polyphenols suppress the growth of harmful bacteria and foster SCFA production, aiding in CRC prevention.

Fermented foods, owing to their probiotics and bioactive compounds, are gaining recognition for their protective role against CRC. These live-microorganism-rich foods—yogurt, kefir, kimchi, and sauerkraut—beneficially affect gut microbiota composition. Research by Leeuwendaal et al. [33] links regular consumption of fermented foods to improved gut health

and reduced CRC risk. Consuming these foods during fermentation increases their nutritional value and generates beneficial substances, emphasizing their dietary significance.

Clinical Implications

Microbiome profiling can predict CRC management. Determining microbial markers related to resistance could enhance the precision of treatments. A precision medicine approach integrating microbiome data can potentially enhance treatment efficacy, reduce CRC incidence in at-risk populations.

Therapeutic Potential

The evolving knowledge on the role of the gut microbiome in CRC offers promising opportunities for new treatments. Promising strategies for significantly altering the treatment landscape of CRC include Fecal Microbiota Transplantation (FMT) and personalized microbiome-based therapies.

Fecal Microbiota Transplantation (FMT)

Fecal Microbiota Transplantation has proven effective in restoring gut microbiome diversity in patients with dysbiosis. Clinical trials of FMT in CRC management have shown promising results, implying an ability to enhance treatment responses and potentially alter disease advancement. In a recent study [34], patients undergoing standard CRC treatments were given FMT, leading to increased microbial diversity and improved clinical outcomes, including decreased inflammation and tumor burden.

While FMT shows promise for CRC treatment, there are barriers preventing its widespread use. The issues of donor selection, transplant protocol standardization, and microbial transfer risks call for substantial effort and attention. Regulatory barriers need to be overcome for FMT to become a standard treatment. Future research should prioritize optimizing FMT protocols, ensuring donor safety, and implementing large-scale clinical trials to definitively guide the application of FMT in CRC management.

Personalized Microbiome-Based Therapies

Personalized medicine is rapidly gaining popularity, especially in the realm of microbiome-based treatments. Healthcare providers could optimize therapeutic outcomes by analyzing

individual microbial profiles. Some microbial taxa have been found to link with improved treatment outcomes, including drug sensitivity to chemotherapy and immunotherapy. Clinicians can select appropriate interventions based on a patient's unique microbiome composition by comprehending the relationships involved [35].

Clinical Trials and Case Studies

To enhance the understanding of the gut microbiome's role in colorectal cancer (CRC) treatment, it is vital to incorporate real-world data through ongoing clinical trials and relevant case studies.

Ongoing Clinical Trials

Clinical trials explore the potential of microbiome modulation for CRC treatment. The article [36] investigates probiotics' effectiveness in CRC patients undergoing chemotherapy. The trial intends to ascertain if certain probiotic strains can mitigate side effects of treatment and enhance patients' general wellbeing. The FMT-CRC Trial investigates how FMT can restore diverse gut microbiota and enhance clinical results for CRC patients with dysbiosis. Restoring a healthy microbiome could potentially improve treatment response and decrease recurrence rates.

Case Studies

Anonymized case studies, besides clinical trials, offer important insights into the effects of microbiome-targeted interventions. A patient with advanced colorectal cancer underwent a dietary and probiotic intervention, resulting in a notable improvement. Six months later, beneficial bacteria, mainly Lactobacillus and Bifidobacterium species, had significantly multiplied in the microbiome. The shift resulted in decreased inflammatory markers and enhanced clinical outcomes, including tumor reduction shown in imaging studies [37].

A specific instance underscored the significance of tailored dietary advice. A patient with a repeated CRC biopsy history followed a diet enriched in fiber, polyphenols and probiotics [38]. Following intervention, an improvement in microbial diversity and a decline in pathogenic taxa was observed, linked to enhanced overall health and diminished recurrence probability.

To ensure accuracy and reproducibility, robust methodologies and validation studies are essential for the integration of microbiome profiling into clinical practice as it advances. The

future of precision medicine hinges on utilizing microbial data for informed treatment decisions in CRC management, thereby enhancing patient outcomes [39].

Personalized Microbiome-Based Therapies

Personalized medicine, especially in the field of microbiome-based therapies, is rapidly gaining popularity. Healthcare providers can optimize therapeutic outcomes by analyzing individual microbial profiles. Some microbial taxa are linked to treatment responses, like susceptibility to chemotherapy and immunotherapy. Knowing these relationships can help clinicians choose targeted interventions based on a patient's distinct microbiome [40].

Recognizing microbial markers linked to resistance could lead to the introduction of complementary therapies, like probiotics or prebiotics, that boost the potency of primary treatments. Current research on the effects of diet and microbiome composition on treatment success is promising [41]. Clinicians can optimize CRC management by combining dietary modifications and microbiome-targeted therapies.

Bacterial Taxon	Role in CRC Pathogenesis	Mechanism of Action
Fusobacterium nucleatum	Promotes inflammation and immune evasion	Induces pro-inflammatory cytokines and inhibits immune responses
Bacteroides fragilis	Induces DNA damage	Produces reactive oxygen species (ROS) that damage DNA
Escherichia coli	Contributes to tumorigenesis	Certain strains produce toxins and induce inflammation
Clostridium sporogenes	Produces butyrate, which has protective effects	Maintains epithelial barrier and modulates immune response
Akkermansia muciniphila	Linked to anti-inflammatory effects	Enhances gut barrier function and promotes mucus production
Bifidobacterium spp.	Involved in maintaining gut health	Ferments dietary fibers, producing beneficial short-chain fatty acids (SCFAs)

Enterobacteriaceae	Associated with dysbiosis and increased CRC risk	High abundance correlates with inflammation and tumor promotion

Table: Roles of Specific Bacterial Taxa in Colorectal Cancer Development.

This table illustrates the roles of specific bacterial taxa in the development of colorectal cancer, highlighting their mechanisms of action. By understanding these interactions, researchers and clinicians can better target therapies aimed at modulating the gut microbiome to improve patient outcomes and potentially reduce CRC incidence [42,43].

More on Biomarkers for Diagnosis and Treatment

New findings in microbiome research suggest potential biomarkers from gut bacteria for the early detection and treatment of colorectal cancer [44]. CRC pathogenesis can be better understood and therapeutic interventions optimized using microbiome-based biomarkers.

Biomarkers for Early Detection

Microbial metabolites, particularly short-chain fatty acids (SCFAs) and secondary bile acids, have emerged as potential non-invasive biomarkers for the early detection of CRC. SCFAs, primarily produced through the fermentation of dietary fibers by beneficial gut bacteria, play crucial roles in maintaining gut health and modulating immune responses. Reduced SCFAs (butyrate included) levels, linked to CRC development, may serve as early detection biomarkers. A 2023 study by Liu et al. [45] revealed significant correlations between lower SCFAs concentrations and CRC stages, suggesting their potential as non-invasive disease indicators.

Additionally, secondary bile acids, formed by gut microbiota from primary bile acids, contribute to CRC pathogenesis [45]. Changes in gut microbiota could result in heightened levels of carcinogenic secondary bile acids, potentially contributing to tumor development. Increased CRC risk is associated with high deoxycholic acid levels, a secondary bile acid. Non-

invasive methods, like stool sampling, can detect microbial metabolites for early detection strategies and enhanced screening protocols.

Microbial Biomarkers for Predicting Treatment Outcomes

CRC patients' treatment outcomes can be predicted by specific microbial signatures in addition to early detection. The effectiveness of chemotherapy and immunotherapy might depend on specific microbial compositions. The studies by Jiang et al. (2024) [46] and Kang et al. (2024) [47] showed that patients with gut microbiota rich in beneficial bacteria such as Akkermansia muciniphila and Faecalibacterium prausnitzii had enhanced resistance to immune checkpoint inhibitors.

The findings [48] suggest microbial profiling may predict patient response to treatment. High levels of Fusobacterium nucleatum, present in CRC patients, suggest a reduced likelihood of response to certain therapies. Beneficial microbes can boost the efficacy of immunotherapy by tuning the immune response in the host. Utilizing microbiome data for personalized treatment strategies can optimize therapeutic outcomes while minimizing adverse effects.

Therapeutic Interventions

Clinical trials have proven certain probiotic strains effective in preventing and treating colorectal cancer. In a randomized controlled trial [49], Lactobacillus rhamnosus GG supplementation decreased CRC incidence in high-risk groups. A study by Kvakova et al. (2022) [49] showed that a multi-strain probiotic improved clinical outcomes in CRC patients by increasing gut microbiota diversity and decreasing inflammation. Probiotics could reduce cancer risk in CRC management by promoting a healthy gut microbiome.

Dietary Influences on Gut Microbiome Composition and CRC Risk

Specific Diets

A Mediterranean diet rich in fruits, vegetables, whole grains, legumes, and healthy fats is linked to greater microbial diversity and lower CRC risk. Following this diet boosts gut health by increasing levels of beneficial bacteria like Bifidobacteria and Lactobacilli. Khavandegar et al. (2024) [50] found higher levels of bacteria producing short-chain fatty acids (SCFAs), linked to anti-inflammatory effects and a stronger gut barrier, among participants following a Mediterranean diet.

A Western diet, rich in red and processed meats, refined carbohydrates, and low in fiber, fuels dysbiosis and enhances the risk of colorectal cancer. According to research by Loke et al. (2020) [51], a high-fat diet can boost the presence of pro-inflammatory bacteria, like Enterobacteriaceae, linked to tumor development. Consuming less red meat and more fiber enhances gut microbiota makeup, lowering colon cancer risk.

Nutritional Interventions

Dietary modifications have demonstrated potential in altering gut microbiota and lowering the risk of colorectal cancer. Consuming more dietary fiber promotes the expansion of advantageous SCFA-producing bacteria, such as Faecalibacterium and Bacteroides. According to a 2021 study by Cronin [52], a high fiber intake decreases the risk of CRC by 25%, and incorporating probiotic-rich fermented foods like yogurt and kefir can promote gut health and enhance microbial diversity.

Future Directions

Future research should elucidate the mechanisms connecting gut microbiome to CRC via metagenomic and metabolomic methods. Longitudinal studies are crucial for unraveling the complex interplay between microbial composition, diet, and colorectal cancer (CRC) progression. Examining the effects of particular dietary modifications on microbial populations and CRC risk may lead to customized dietary advice for CRC prevention and care.

Ethical and Societal Implications

The exploration of the gut microbiome's influence on colorectal cancer (CRC) raises important ethical considerations and societal implications, particularly regarding genetic editing technologies and the potential for microbiome-based public health interventions.

Genetic Editing of the Microbiome

Gene-editing technologies like CRISPR-Cas9 have revolutionized microbiome research, enabling microbial communities to be modified for therapeutic purposes. By targeting beneficial microbial strains and reducing pathogenic ones, this approach could optimize the microbiome. Genetic editing in the microbiome raises substantial ethical concerns [53].

The gut microbiota's complex nature makes predicting the outcomes of modifying it uncertain. Modifying particular microbial genes could potentially result in the emergence of harmful

pathogens or the disruption of advantageous microbial relationships. Ethical concerns surround consent and the possibility of unregulated manipulation of microbial communities [54].

Broader ethical considerations arise regarding the potential for "designer microbiomes," which could result in disparities in access based on personalized interventions. cut-edge microbiome therapies may widen healthcare disparities if not accessible equally to all populations. In microbiome research and therapy development, it's crucial to prioritize the broader population's benefits, especially for underserved communities [55].

Microbiome as a Public Health Tool

Implementing microbiome research into public health strategies for CRC prevention entails advantages and obstacles. Dietary recommendations and probiotics, which aim to improve microbiome health, may decrease CRC risk. Social implications of these programs must be meticulously considered in their design.

The success of microbiome-based interventions depends significantly on their accessibility. Public health strategies need to address socioeconomic disparities impacting access to nutritious food, probiotics, and advanced microbiome testing. Low-income individuals' restricted access to fresh produce and quality probiotics hampers their ability to maintain a healthy microbiome, exacerbating health inequalities. To include and benefit all populations, particularly those at higher risk for CRC, interventions derived from microbiome research must be designed inclusively and equitably [56].

Global Perspectives

The incidence of colorectal cancer significantly varies geographically, influenced by factors like lifestyle, diet, and socioeconomic status. The highest CRC rates are reported by the Global Cancer Observatory in North America and Europe, with an age-standardized incidence ranging from 25 to 40 cases per 100,000 individuals. In regions like Asia and sub-Saharan Africa, rates can be as low as 5 to 10 cases per 100,000 inhabitants. This disparity highlights the urgency for targeted public health initiatives and a deeper exploration of the underlying causes [57].

The gut microbiome composition variations could significantly explain the disparities in CRC incidence. Research shows Western populations have less microbial diversity with higher levels of pathogenic strains like Fusobacterium nucleatum and Bacteroides fragilis, linked to CRC. Populations with traditional diets in rural Asia and Africa typically display greater microbial

diversity, with an emphasis on beneficial bacteria linked to anti-inflammatory effects and cancer prevention [58,59].

CRC's epidemiology is complicated by various lifestyle factors. Urban residents, with their sedentary lifestyles and diets heavy in processed food and red meat, have higher colorectal cancer rates compared to those in rural areas, whose more active lifestyles and fiber-rich, plant-based diets offer protection. The study in China revealed a roughly 30% higher CRC incidence rate among urban residents, linked to their higher consumption of animal products [60].

Socioeconomic status also plays a crucial role in CRC epidemiology. Higher-income individuals are more likely to adopt Western dietary habits, leading to an increased risk of CRC. In contrast, lower-income populations often face barriers to accessing health-promoting foods, contributing to disparities in gut microbiome composition and CRC risk. Public health strategies targeting these populations, particularly in urban areas, could significantly impact CRC prevention efforts by promoting healthier dietary choices and increased physical activity, ultimately improving gut microbiome health and reducing cancer risk.

These findings highlight the importance of understanding the complex interplay between geography, lifestyle, and microbial health in addressing the global burden of CRC. By acknowledging these variations and their implications, we can better inform public health initiatives aimed at mitigating CRC incidence and enhancing the health of populations worldwide.

Conclusion

The potential of microbiome research in colorectal cancer (CRC) management is promising, but it is essential to navigate the ethical dilemmas associated with genetic editing and address the societal implications of microbiome-based public health initiatives. Prioritizing equity, transparency, and community engagement allows researchers and healthcare policymakers to harness the benefits of microbiome research while safeguarding ethical standards and promoting societal well-being.

Studies on the gut microbiome reveal potential possibilities for CRC prevention and treatment. Targeted interventions are necessitated by the complex interplay between microbial diversity, immune modulation, inflammation, and tumorigenesis. The identification of certain bacterial

taxa and microbial metabolites related to CRC development indicates the growing potential for personalized medicine based on microbial profiling.

Evidence supporting microbiome-targeted therapies—such as probiotics, dietary modifications, and fecal microbiota transplants (FMT)—suggests a future where treatment strategies can be tailored to an individual's microbial landscape. These approaches not only promise to improve therapeutic efficacy but also reduce adverse treatment outcomes and enhance the quality of life for CRC patients. Integrating microbiome biomarkers into CRC detection protocols could revolutionize screening methods with more accessible, non-invasive options for at-risk populations.

Replace

However, exploring the gut microbiome introduces significant ethical and societal considerations. As gene-editing technologies like CRISPR-Cas9 enable modifications of microbial communities, the potential for unforeseen consequences necessitates a cautious and regulated approach. To avoid exacerbating health disparities, microbiome-based therapies must be accessible to all, including underserved populations.

Moving forward, interdisciplinary collaboration among microbiome researchers, oncologists, dietitians, and public health experts is crucial for translating these scientific insights into practical, patient-centered applications. Future research should focus on large-scale, longitudinal studies to better understand the causative relationships between diet, microbial composition, and CRC progression. Utilizing the full capacity of microbiome science significantly enhances CRC prevention and treatment, reducing the global burden of the disease.

Disclosure

Authors contribution:

Conceptualisation: Wiktor Grela, Aleksandra Górska, Natalia Gniaź

Methodology: Alicja Dziedzic, Daria Furtak

Formal analysis: Dawid Tulej, Dominika Marciniuk

Investigation: Jagoda Niewiadomska, Natalia Marko, Paulina Głogowska

Writing - Rough Preparation: Wiktor Grela, Natalia Gniaź, Aleksandra Górska, Alicja Dziedzic
Writing - Review and Editing: Wiktor Grela, Daria Furtak, Dominika Marciniuk, Dawid Tulej
Visualisation: Paulina Głogowska, Natalia Marko, Jagoda Niewiadomska

All authors have read and agreed with the published version of the manuscript.

Conflicts of Interest: The authors declare no conflicts of interest.

Funding Statement: No external funding was received to perform this review.

Board Statement: Not applicable – this review included an analysis of the available literature.

Statement of Informed Consent: Not applicable.

References

1. Turnbaugh PJ, Ley RE, Hamady M, et al. The human microbiome project. *Nature*. 2007;449(7164):804-810. doi:10.1038/nature06244.
2. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. *Nature*. 2012;486(7402):207-214. doi:10.1038/nature11234.
3. Gilbert JA, Quinn RA, Debelius J, et al. Microbiome-wide association studies link dynamic microbial consortia to disease. *Nature*. 2016;535(7610):94-103. doi:10.1038/nature18850.
4. Baxter NT, Zackular JP, Chen GY, Schloss PD. Structure of the gut microbiome following colonization with human feces determines colonic tumor burden. *Microbiome*. 2014;2:20. doi:10.1186/2049-2618-2-20.
5. Koyande N, Gangopadhyay M, Thatikonda S, Rengan AK. The role of gut microbiota in the development of colorectal cancer: a review. *Int J Colorectal Dis*. 2022;37(7):1509-1523. doi:10.1007/s00384-022-04192-w.
6. Chen H, Jiao J, Wei M, et al. Metagenomic analysis of the interaction between the gut microbiota and colorectal cancer: a paired-sample study based on the GMrepo database. *Gut Pathog*. 2022;14(1):48. doi:10.1186/s13099-022-00527-8.
7. Zhang HP, Li SY, Wang JP, Lin J. Clinical significance and biological roles of cyclins in gastric cancer. *Onco Targets Ther*. 2018;11:6673-6685. doi:10.2147/OTT.S171716.
8. Li P, Gao L, Cui T, Zhang W, Zhao Z, Chen L. Cops5 safeguards genomic stability of embryonic stem cells through regulating cellular metabolism and DNA repair. *Proc Natl Acad Sci U S A*. 2020;117(5):2519-2525. doi:10.1073/pnas.1915079117.
9. Anderson SM, Sears CL. The Role of the Gut Microbiome in Cancer: A Review, With Special Focus on Colorectal Neoplasia and Clostridioides difficile. *Clin Infect Dis*. 2023;77(Suppl 6)
   . doi:10.1093/cid/ciad640.
10. Steele CC, Pirkle JRA, Davis IR, Kirkpatrick K. Dietary effects on the determinants of food choice: Impulsive choice, discrimination, incentive motivation, preference, and liking in male rats. *Appetite*. 2019;136:160-172. doi:10.1016/j.appet.2019.01.023.
11. Williamson AJ, Jacobson R, van Praagh JB, et al. Enterococcus faecalis promotes a migratory and invasive phenotype in colon cancer cells. *Neoplasia*. 2022;27:100787. doi:10.1016/j.neo.2022.100787

12. Siddiqui R, Boghossian A, Alharbi AM, Alfahemi H, Khan NA. The Pivotal Role of the Gut Microbiome in Colorectal Cancer. *Biology (Basel)*. 2022;11(11):1642. Published 2022 Nov 9. doi:10.3390/biology11111642
13. Brennan CA, Clay SL, Lavoie SL, et al. *Fusobacterium nucleatum* drives a pro-inflammatory intestinal microenvironment through metabolite receptor-dependent modulation of IL-17 expression. *Gut Microbes*. 2021;13(1):1987780. doi:10.1080/19490976.2021.1987780
14. Zhu Y, Li X. Advances of Wnt Signalling Pathway in Colorectal Cancer. *Cells*. 2023;12(3):447. Published 2023 Jan 30. doi:10.3390/cells12030447
15. He K, Gan WJ. Wnt/β-Catenin Signaling Pathway in the Development and Progression of Colorectal Cancer. *Cancer Manag Res*. 2023;15:435-448. Published 2023 May 23. doi:10.2147/CMAR.S411168
16. Cheng WT, Kantilal HK, Davamani F. The Mechanism of *Bacteroides fragilis* Toxin Contributes to Colon Cancer Formation. *Malays J Med Sci*. 2020;27(4):9-21. doi:10.21315/mjms2020.27.4.2
17. Dai Z, Zhang J, Wu Q, et al. The role of microbiota in the development of colorectal cancer. *Int J Cancer*. 2019;145(8):2032-2041. doi:10.1002/ijc.32017
18. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. *Cold Spring Harb Perspect Biol*. 2009;1(6):a001651. doi:10.1101/cshperspect.a001651
19. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. *Signal Transduct Target Ther*. 2017;2:17023-. doi:10.1038/sigtrans.2017.23
20. Hou X, Zheng Z, Wei J, Zhao L. Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer. *Front Immunol*. 2022;13:1030745. Published 2022 Nov 8. doi:10.3389/fimmu.2022.1030745
21. Roy R, Singh SK. The Microbiome Modulates the Immune System to Influence Cancer Therapy. *Cancers (Basel)*. 2024;16(4):779. Published 2024 Feb 14. doi:10.3390/cancers16040779
22. Tojjari A, Abushukair H, Saeed A. The Crosstalk between Microbiome and Immunotherapeutics: Myth or Reality. *Cancers (Basel)*. 2022;14(19):4641. Published 2022 Sep 24. doi:10.3390/cancers14194641
23. Genua F, Raghunathan V, Jenab M, Gallagher WM, Hughes DJ. The Role of Gut Barrier Dysfunction and Microbiome Dysbiosis in Colorectal Cancer Development. *Front Oncol*. 2021;11:626349. Published 2021 Apr 15. doi:10.3389/fonc.2021.626349

24. Martin-Gallausiaux C, Marinelli L, Blottière HM, Larraufie P, Lapaque N. SCFA: mechanisms and functional importance in the gut. *Proc Nutr Soc*. 2021;80(1):37-49. doi:10.1017/S0029665120006916
25. Cheng WT, Kantilal HK, Davamani F. The Mechanism of *Bacteroides fragilis* Toxin Contributes to Colon Cancer Formation. *Malays J Med Sci*. 2020;27(4):9-21. doi:10.21315/mjms2020.27.4.2
26. Quaglio AEV, Grillo TG, De Oliveira ECS, Di Stasi LC, Sassaki LY. Gut microbiota, inflammatory bowel disease and colorectal cancer. *World J Gastroenterol*. 2022;28(30):4053-4060. doi:10.3748/wjg.v28.i30.4053
27. Ranjbar M, Salehi R, Haghjooy Javanmard S, et al. The dysbiosis signature of Fusobacterium nucleatum in colorectal cancer-cause or consequences? A systematic review [published correction appears in Cancer Cell Int. 2022 Mar 26;22(1):134. doi: 10.1186/s12935-022-02549-3]. *Cancer Cell Int*. 2021;21(1):194. Published 2021 Apr 6. doi:10.1186/s12935-021-01886-z
28. Slavin J. Fiber and prebiotics: mechanisms and health benefits. *Nutrients*. 2013;5(4):1417-1435. Published 2013 Apr 22. doi:10.3390/nu5041417
29. Veettil SK, Teerawattanapong N, Ching SM, et al. Effects of chemopreventive agents on the incidence of recurrent colorectal adenomas: a systematic review with network meta-analysis of randomized controlled trials. *Onco Targets Ther*. 2017;10:2689-2700. Published 2017 May 23. doi:10.2147/OTT.S127335
30. Jadhav A, Jagtap S, Vyavahare S, Sharbidre A, Kunchiraman B. Reviewing the potential of probiotics, prebiotics and synbiotics: advancements in treatment of ulcerative colitis. *Front Cell Infect Microbiol*. 2023;13:1268041. Published 2023 Dec 8. doi:10.3389/fcimb.2023.1268041
31. Aune D, Chan DS, Lau R, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. *BMJ*. 2011;343:d6617. Published 2011 Nov 10. doi:10.1136/bmj.d6617
32. Gómez-Pinilla F. Brain foods: the effects of nutrients on brain function. *Nat Rev Neurosci*. 2008;9(7):568-578. doi:10.1038/nrn2421
33. Leeuwendaal NK, Stanton C, O'Toole PW, Beresford TP. Fermented Foods, Health and the Gut Microbiome. *Nutrients*. 2022;14(7):1527. Published 2022 Apr 6. doi:10.3390/nu14071527

34. Biazzo M, Deidda G. Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases. *J Clin Med*. 2022;11(14):4119. Published 2022 Jul 15. doi:10.3390/jcm11144119
35. Behrouzi A, Nafari AH, Siadat SD. The significance of microbiome in personalized medicine. *Clin Transl Med*. 2019;8(1):16. Published 2019 May 13. doi:10.1186/s40169-019-0232-y
36. Dikeocha IJ, Al-Kabsi AM, Eid EEM, Hussin S, Alshawsh MA. Probiotics supplementation in patients with colorectal cancer: a systematic review of randomized controlled trials. *Nutr Rev*. 2021;80(1):22-49. doi:10.1093/nutrit/nuab006
37. Zhen J, Liu C, Liao F, Zhang J, Xie H, Tan C, Dong W. The global research of microbiota in colorectal cancer screening: a bibliometric and visualization analysis. Front Oncol. 2023 May 5;13:1169369. doi: 10.3389/fonc.2023.1169369. PMID: 37213286; PMCID: PMC10196493.
38. John Kenneth M, Tsai HC, Fang CY, Hussain B, Chiu YC, Hsu BM. Diet-mediated gut microbial community modulation and signature metabolites as potential biomarkers for early diagnosis, prognosis, prevention and stage-specific treatment of colorectal cancer. *J Adv Res*. 2023;52:45-57. doi:10.1016/j.jare.2022.12.015
39. Fong W, Li Q, Yu J. Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer. *Oncogene*. 2020;39(26):4925-4943. doi:10.1038/s41388-020-1341-1
40. Behrouzi A, Nafari AH, Siadat SD. The significance of microbiome in personalized medicine. *Clin Transl Med*. 2019;8(1):16. Published 2019 May 13. doi:10.1186/s40169-019-0232-y
41. Aggarwal N, Kitano S, Puah GRY, Kittelmann S, Hwang IY, Chang MW. Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies. *Chem Rev*. 2023;123(1):31-72. doi:10.1021/acs.chemrev.2c00431
42. Ulger Y, Delik A, Akkız H. Gut Microbiome and colorectal cancer: discovery of bacterial changes with metagenomics application in Turkısh population. *Genes Genomics*. 2024;46(9):1059-1070. doi:10.1007/s13258-024-01538-2
43. Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. *Nat Rev Gastroenterol Hepatol*. 2019;16(11):690-704. doi:10.1038/s41575-019-0209-8

44. Zwezerijnen-Jiwa FH, Sivov H, Paizs P, Zafeiropoulou K, Kinross J. A systematic review of microbiome-derived biomarkers for early colorectal cancer detection. *Neoplasia*. 2023;36:100868. doi:10.1016/j.neo.2022.100868
45. Liu Y, Lau HC, Yu J. Microbial metabolites in colorectal tumorigenesis and cancer therapy. *Gut Microbes*. 2023;15(1):2203968. doi:10.1080/19490976.2023.2203968
46. Jiang S, Ma W, Ma C, Zhang Z, Zhang W, Zhang J. An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome. *Gut Microbes*. 2024;16(1):2341717. doi:10.1080/19490976.2024.2341717
47. Kang X, Lau HC, Yu J. Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy. *Cell Rep Med*. 2024;5(4):101478. doi:10.1016/j.xcrm.2024.101478
48. Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. *Cell*. 2017;170(3):548-563.e16. doi:10.1016/j.cell.2017.07.008
49. Kvakova M, Kamlarova A, Stofilova J, Benetinova V, Bertkova I. Probiotics and postbiotics in colorectal cancer: Prevention and complementary therapy. *World J Gastroenterol*. 2022;28(27):3370-3382. doi:10.3748/wjg.v28.i27.3370
50. Khavandegar A, Heidarzadeh A, Angoorani P, et al. Adherence to the Mediterranean diet can beneficially affect the gut microbiota composition: a systematic review. *BMC Med Genomics*. 2024;17(1):91. Published 2024 Apr 17. doi:10.1186/s12920-024-01861-3
51. Loke YL, Chew MT, Ngeow YF, Lim WWD, Peh SC. Colon Carcinogenesis: The Interplay Between Diet and Gut Microbiota. *Front Cell Infect Microbiol*. 2020;10:603086. Published 2020 Dec 8. doi:10.3389/fcimb.2020.603086
52. Cronin P, Joyce SA, O'Toole PW, O'Connor EM. Dietary Fibre Modulates the Gut Microbiota. *Nutrients*. 2021;13(5):1655. Published 2021 May 13. doi:10.3390/nu13051655
53. Ali N, Vora C, Mathuria A, Kataria N, Mani I. Advances in CRISPR-Cas systems for gut microbiome. *Prog Mol Biol Transl Sci*. 2024;208:59-81. doi:10.1016/bs.pmbts.2024.07.008
54. Lerner A, Benzvi C, Vojdani A. The Potential Harmful Effects of Genetically Engineered Microorganisms (GEMs) on the Intestinal Microbiome and Public Health. *Microorganisms*. 2024;12(2):238. Published 2024 Jan 23. doi:10.3390/microorganisms12020238

55. O'Doherty KC, Virani A, Wilcox ES. The Human Microbiome and Public Health: Social and Ethical Considerations. *Am J Public Health*. 2016;106(3):414-420. doi:10.2105/AJPH.2015.302989
56. Amato KR, Arrieta MC, Azad MB, et al. The human gut microbiome and health inequities. *Proc Natl Acad Sci U S A*. 2021;118(25):e2017947118. doi:10.1073/pnas.2017947118
57. Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A Review of Colorectal Cancer in Terms of Epidemiology, Risk Factors, Development, Symptoms and Diagnosis. *Cancers (Basel)*. 2021;13(9):2025. Published 2021 Apr 22. doi:10.3390/cancers13092025
58. Tortora SC, Bodiwala VM, Quinn A, Martello LA, Vignesh S. Microbiome and colorectal carcinogenesis: Linked mechanisms and racial differences. *World J Gastrointest Oncol*. 2022;14(2):375-395. doi:10.4251/wjgo.v14.i2.375
59. Herlo LF, Salcudean A, Sirli R, et al. Gut Microbiota Signatures in Colorectal Cancer as a Potential Diagnostic Biomarker in the Future: A Systematic Review. *Int J Mol Sci*. 2024;25(14):7937. Published 2024 Jul 20. doi:10.3390/ijms25147937
60. Ma T, Tu K, Ou Q, Fang Y, Zhang C. Comparing the Associations of Dietary Patterns Identified through Principal Component Analysis and Cluster Analysis with Colorectal Cancer Risk: A Large Case-Control Study in China. *Nutrients*. 2023;16(1):147. Published 2023 Dec 31. doi:10.3390/nu16010147